杨鹏，教授、博导、药学院副院长、原创药物研究院常务副院长、国家杰出青年科学基金获得者，入选国家高层次青年人才（2018年）、江苏省“双创人才”（2019年）和“双创团队领军人才”（2020年）、江苏省百篇优秀博士学位论文指导教师（2022年）、江苏省“攀登人才”（2024年）。

  致力于癌症、代谢性疾病相关的靶标发现与小分子药物研究，发表学术论文80余篇，其中以通讯作者在Nat. Commun.、Acta Pharm Sin B（5篇）、J. Med. Chem.（13篇，含2篇封面）、Eur. J. Med. Chem. （6篇）等发表论文41篇；主持国家重点研发计划课题、国自然面上等纵向科研项目19项；以第一发明人申请专利42项（中国35项，已授权24项；国际7项）；主持或参与完成多项新药研究，五个候选药物成功转让给医药企业（总额1.76亿），一个已完成II期临床研究。

  目前，担任《中国医药生物技术》常务编委，《中国药物评价》、《中国药物化学杂志》、《Biomedical and Environmental Sciences》、《中国药科大学学报》编委，《药学进展》、《药学学报》和Acta Pharm Sin B青年编委，中国药学会药物化学专业委员会委员、中国药学会老年药学专业委员会委员、中国生物医药产业链创新与转化联盟药物研发专业委员会副主委。

1.  Zhu Y.#, Ye X.#, Wu Y.#, Shen H.#, Cai Z., Xia F., Min W., Hou Y., Wang L., Wang X.*, Xiao Y.*, Yang P.*. Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting C797S Mutation. J. Med. Chem. 2024, 67, 9, 7283–7300.

2.  Sun C.#, He Y.#, Wang G.#, Zhang G.#, Zhang Y., Shen H., Hu L., Sun Y., Jiang B., Wang X., Yuan K., Min W., Wang L., Sun H.*, Xiao Y.*, Yang P.*. Design, synthesis, and antitumor activity evaluation of novel VISTA small molecule inhibitors. J. Med. Chem. 2024, 67, 5, 3590–3605.

3.   Yuan K.#, Xia F.#, Shen H.#, Li Q.#, Zheng M., Chen W., Yang H., Zhuang X., Zhang X.*, Xiao Y.*, Yang P.*. Discovery of potent, selective, and orally bioavailable DYRK2 inhibitors for prostate cancer treatment. J. Med. Chem. 2023, 66, 23, 16235-16256.

4.   Zhu Y.#, Ye X.#, Shen H.#, Li J., Cai Z., Min W., Hou Y., Wu Y., Wang L., Wang X.*, Xiao Y.*, Yang P.*. Discovery of Novel Fourth-Generation EGFR Inhibitors to Overcome C797S-Mediated Resistance. J. Med. Chem. 2023,  66, 14633-14652.

5.   Dong H.#, Ye X.#, Zhu Y.#, Shen H., Shen H., Chen W., Ji M., Zheng M., Wang K., Cai Z., Sun H.*, Xiao Y.*, Yang P.*. Discovery of Potent and Wild-Type-Sparing Fourth-Generation EGFR Inhibitors for Treatment of Osimertinib-Resistance NSCLC. J. Med. Chem. 2023, 66, 6849-6868.

6.   Yuan K.#, Shen H.#, Zheng M.#, Xia F.#, Li Q., Chen W., Ji M., Yang H., Zhuang X., Cai Z., Min W., Wang X.*, Xiao Y.*, Yang P.*. Discovery of potent DYRK2 inhibitors with high selectivity, great solubility, and excellent safety properties for the treatment of prostate cancer. J. Med. Chem. 2023, 66, 4215-4230 (封面文章).

7.   Sun C.#, Yin M.#, Cheng Y.#, Kuang Z., Liu X., Wang G., Wang X., Yuan K., Min W., Dong J., Hou Y., Hu L., Zhang G., Pei W., Wang L., Sun Y., Yu X., Xiao Y.*, Deng H.*, Yang P.*. Novel small-molecule PD-L1 inhibitor induces PD-L1 internalization and optimizes the immune microenvironment. J. Med. Chem. 2023, 66, 2064-2083 (封面文章).

8.   Sun C.#, Cheng Y.#, Liu X.#, Wang G., Min W., Wang X., Yuan K., Hou Y., Li J., Zhang H., Dong H., Wang L., Lou C., Sun Y., Yu X., Deng H.*, Xiao Y.*, Yang P.*. Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents. Acta Pharm. Sin. B 2022, 12(12): 4446-4457.

9.   Chen W.#, Ji M.#, Cheng H.#, Zheng M., Xia F., Min W., Yang H., Wang X., Wang L., Cao L.*, Yuan K.*, Yang P.*. Discovery, Optimization, and Evaluation of Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer. J. Med. Chem. 2022, 65, 22, 15102-15122.

10. Hou Y.#, Zhang F.#, Min W.#, Yuan K., Kuang W., Wang X., Zhu Y., Sun C., Xia F., Wang Y., Zhang H., Wang L., Yang P.*. Discovery of Novel Phosphoinositide-3-Kinase α Inhibitors with High Selectivity, Excellent Bioavailability, and Long-Acting Efficacy for Gastric Cancer. J. Med. Chem. 2022, 65, 9873-9892.

11. Yuan K.#, Li Z.#, Kuang W.#, Wang X.#, Ji M., Chen W., Li J., Min W., Sun C., Ye X., Lu M., Wang L., Ge H., Jiang Y.*, Hao H.*, Xiao Y.*, Yang P.*. Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) with a highly selective inhibitor for the treatment of prostate cancer, Nat. Commun. 2022, 13:2903.

12. Yuan K.#, Ji M.#, Xie S.#, Qiu Z., Chen W., Min W., Xia F., Zheng M., Wang X., Li J., Hou Y., Kuang W., Wang L., Gu W.*, Li Z.*, Yang P.*, Discovery of Dual CDK6/PIM1 Inhibitors with a Novel Structure, High Potency, and Favorable Druggability for the Treatment of Acute Myeloid Leukemia. J. Med. Chem. 2022, 65(1), 857-875.